Mobidiag is a commercial-stage, revenue-generating molecular diagnostics company offering the Amplidiag® and Novodiag® platforms for detection of infectious diseases and antimicrobial resistance. Its solutions enable rapid detection of pathogens and potential resistance to antibiotics and are available through Mobidiag’s sales teams and local distributors. The company says it has an extensive portfolio of diagnostic solutions for gastrointestinal and respiratory infections, healthcare-associated infections and AMR management. Mobidiag plans to use new financing to advance research and development, and to further validate and commercialise new molecular diagnostic tests on its platforms. Management is working to ramp up manufacturing capacity to meet growing adoption by key laboratories throughout Europe. Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, the UK and Sweden. Mobidiag develops molecular diagnostic platforms (Amplidiag and Novodiag) targeting antimicrobial resistance and other unmet diagnostic needs. The company is using its Novodiag platform to build a fast, simple, reliable syndromic assay to detect sepsis directly from blood within two hours. Mobidiag has prior experience in sepsis diagnostics with its former Prove-it product, which detected 80 targets from blood cultures. The firm sells into multiple healthcare settings, initially focusing on gastrointestinal diseases and superbugs through direct sales and distributors, and is rapidly building a leading position in European markets. Mobidiag is revenue generating, fast growing, employs more than 100 staff, and is headquartered in Espoo, Finland with subsidiaries in France, the UK and Sweden. The company states the sepsis assay program is progressing after completing key milestones tied to prior funding. Mobidiag is a commercial-stage molecular diagnostics company offering the Amplidiag® and Novodiag® platforms for rapid detection of infectious diseases and antimicrobial resistance. Its Novodiag® platform is an automated, on-demand solution positioned for small and decentralized labs as well as larger laboratories, emphasizing low hands-on time, ease of use, random access and reliable results. The company has completed extensive R&D and clinical validation and reports that Novodiag® has been commercially adopted by many laboratories throughout Europe. Mobidiag plans to use new financing to advance R&D, further validate and commercialise molecular diagnostic tests and expand its product pipeline. The firm emphasizes building a comprehensive portfolio of diagnostics tests to increase the platform content and commercial reach. Mobidiag commercialises molecular diagnostics solutions including the Novodiag® platform and Amplidiag® products, targeting rapid detection of pathogens and antibiotic resistances. The Novodiag® system combines real-time PCR and microarray technologies to analyse samples in a disposable cartridge and deliver results in about one hour. Mobidiag announced a €10m equity investment from Autobio and a joint venture to commercialise Novodiag® in China, strengthening its cash position. Proceeds from the €10m investment will be used to grow the product portfolio, accelerate assay development for Novodiag® and enhance manufacturing capabilities. The company will also leverage the China JV to register the platform and initial assays with the NMPA and to set up local manufacturing of components and disposables. Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, the UK and Sweden. Mobidiag develops and commercialises the Amplidiag and Novodiag platforms for detection of gastrointestinal infections and multi‑drug resistant organisms. Its products are designed to bring DNA‑based testing closer to patients in a user‑friendly and cost‑effective format suitable for laboratories of varying size and throughput. The company plans to scale up production of Novodiag instruments and disposable cartridges and to strengthen its global sales and marketing activities. Financially, Mobidiag completed an additional €4 million capital increase through a public financing round to support global business development and capacity for the Novodiag solution. Established in 2000 and serving the clinical diagnostics market since 2008, Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, the UK and Sweden and R&D centres in Finland and France.

Total raised

$94M

Funding rounds

8

Latest round

Debt Financing

Latest activity

Jun 2020